skip to the main content

Boditech Med signed MOU for CRISPR Cas system based diagnosis with nSAGE

We are proud to announce that Boditech Med had signed a memorandum of understanding (MOU) with nSAGE for cooperation in the development of a next-generation diagnostic platform using the CRISPR Cas system.

nSAGE is a company that possesses the world's largest Cas protein pool and specializes in R&D of anticancer cell therapy (CAR-NK) and stem cell therapy. 

Genetic scissors are a tool to treat major diseases by removing genes or by editing and inserting specific gene regions. Among these technologies, the CRISPR-Cas system, the third-generation technology, has the highest accuracy and efficiency among gene scissors to date. This technology can be used not only for various anticancer drugs, but also for the development of therapeutic agents for genetic diseases, metabolic diseases, and autoimmune diseases. 

Recently, as it can be used as an original technology for molecular diagnostics, major biotechnology companies are actively seeking various convergence with the diagnostic industry. It can be directly used to develop a diagnostic kit for the COVID-19. It is expected to be a point of care (POC) diagnostics kit with high a sensitivity (>99%), similar to RT-PCR. This is a product that perfectly fits the era of ‘With Corona’, which is expanding in major regions such as the United States and the United Kingdom.

A company official said, “In the near future, it is expected that products to which related to gene scissors-based technology will be widely applied in diagnosis of various diseases. Boditech Med and nSAGE are planning to expand the synergy of their specialized technologies, and in addition to the COVID-19 diagnostic kit, they plan to develop and commercialize CRISPR-Cas-based diagnostic devices and various diagnostic kits.”